Clinical Trials Browser

Phase 1 × Terminated × entinostat × Clear all

NCT00754312 2022-06-06

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT03924245 2022-04-04

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1 Terminated

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Phase 1 Terminated

1 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Phase 1 Terminated

Prostate Adenocarcinoma

NCT01886573 2016-11-18

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01159301 2013-09-19

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute